Effector functions of natural killer cell subsets in the control of hematological malignancies

Angela Gismondi, Helena Stabile, Paolo Nisti, Angela Santoni

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists. Therefore, it is of great interest to explore novel therapeutic strategies to obtain long-term remission. Immune effector cells, and especially natural killer (NK) cells, play a crucial role in the control of hematological malignancies. In this regard, the efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated graft versus leukemia effect without the risk of inducing graft versus host disease. Alloreactive donor NK cells generated following hematopoietic stem cell transplantation ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell effector functions against resistant leukemia cells, novel immunotherapeutic strategies are oriented to the identification, isolation, expansion, and administration of particular NK cell subsets endowed with multifunctional anti-tumor potential and tropism toward tumor sites. Moreover, the relationship between the emergence and persistence of distinct NK cell subsets during post-graft reconstitution and the maintenance of a remission state is still rather unclear.

Original languageEnglish
Article number567
JournalFrontiers in Immunology
Volume6
Issue numberNOV
DOIs
Publication statusPublished - 2015

Fingerprint

Hematologic Neoplasms
Natural Killer Cells
Leukemia
Transplants
Tropism
Hematopoietic Stem Cell Transplantation
Residual Neoplasm
Stem Cell Transplantation
Graft vs Host Disease
Neoplasms
Therapeutics
Maintenance
Tissue Donors
Recurrence

Keywords

  • Hematological malignancies
  • HSCT
  • NK cell subsets
  • NK cell therapy
  • NK cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Effector functions of natural killer cell subsets in the control of hematological malignancies. / Gismondi, Angela; Stabile, Helena; Nisti, Paolo; Santoni, Angela.

In: Frontiers in Immunology, Vol. 6, No. NOV, 567, 2015.

Research output: Contribution to journalArticle

Gismondi, Angela ; Stabile, Helena ; Nisti, Paolo ; Santoni, Angela. / Effector functions of natural killer cell subsets in the control of hematological malignancies. In: Frontiers in Immunology. 2015 ; Vol. 6, No. NOV.
@article{995022208cca469cb9e74bd34dc0d41f,
title = "Effector functions of natural killer cell subsets in the control of hematological malignancies",
abstract = "Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists. Therefore, it is of great interest to explore novel therapeutic strategies to obtain long-term remission. Immune effector cells, and especially natural killer (NK) cells, play a crucial role in the control of hematological malignancies. In this regard, the efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated graft versus leukemia effect without the risk of inducing graft versus host disease. Alloreactive donor NK cells generated following hematopoietic stem cell transplantation ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell effector functions against resistant leukemia cells, novel immunotherapeutic strategies are oriented to the identification, isolation, expansion, and administration of particular NK cell subsets endowed with multifunctional anti-tumor potential and tropism toward tumor sites. Moreover, the relationship between the emergence and persistence of distinct NK cell subsets during post-graft reconstitution and the maintenance of a remission state is still rather unclear.",
keywords = "Hematological malignancies, HSCT, NK cell subsets, NK cell therapy, NK cells",
author = "Angela Gismondi and Helena Stabile and Paolo Nisti and Angela Santoni",
year = "2015",
doi = "10.3389/fimmu.2015.00567",
language = "English",
volume = "6",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "NOV",

}

TY - JOUR

T1 - Effector functions of natural killer cell subsets in the control of hematological malignancies

AU - Gismondi, Angela

AU - Stabile, Helena

AU - Nisti, Paolo

AU - Santoni, Angela

PY - 2015

Y1 - 2015

N2 - Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists. Therefore, it is of great interest to explore novel therapeutic strategies to obtain long-term remission. Immune effector cells, and especially natural killer (NK) cells, play a crucial role in the control of hematological malignancies. In this regard, the efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated graft versus leukemia effect without the risk of inducing graft versus host disease. Alloreactive donor NK cells generated following hematopoietic stem cell transplantation ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell effector functions against resistant leukemia cells, novel immunotherapeutic strategies are oriented to the identification, isolation, expansion, and administration of particular NK cell subsets endowed with multifunctional anti-tumor potential and tropism toward tumor sites. Moreover, the relationship between the emergence and persistence of distinct NK cell subsets during post-graft reconstitution and the maintenance of a remission state is still rather unclear.

AB - Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists. Therefore, it is of great interest to explore novel therapeutic strategies to obtain long-term remission. Immune effector cells, and especially natural killer (NK) cells, play a crucial role in the control of hematological malignancies. In this regard, the efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated graft versus leukemia effect without the risk of inducing graft versus host disease. Alloreactive donor NK cells generated following hematopoietic stem cell transplantation ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell effector functions against resistant leukemia cells, novel immunotherapeutic strategies are oriented to the identification, isolation, expansion, and administration of particular NK cell subsets endowed with multifunctional anti-tumor potential and tropism toward tumor sites. Moreover, the relationship between the emergence and persistence of distinct NK cell subsets during post-graft reconstitution and the maintenance of a remission state is still rather unclear.

KW - Hematological malignancies

KW - HSCT

KW - NK cell subsets

KW - NK cell therapy

KW - NK cells

UR - http://www.scopus.com/inward/record.url?scp=84949678965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949678965&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2015.00567

DO - 10.3389/fimmu.2015.00567

M3 - Article

AN - SCOPUS:84949678965

VL - 6

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - NOV

M1 - 567

ER -